GILEAD SCIENCES, INC. 4

Chairman & CEO Daniel Patrick O'Day sold 15,000 shares of Gilead Sciences, Inc. common stock on July 1, 2026 under a Rule 10b5-1 plan.

On July 1, 2026, Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day sold an aggregate 15,000 shares of Gilead common stock in two open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026. The first sale involved 11,900 shares at an average price of approximately $126.09 per share, and the second involved 3,100 shares at an average price of approximately $127.08 per share, with execution prices ranging from $125.59 to $127.44. Following these sales, O'Day continued to hold 607,133 shares of Gilead common stock, representing a substantial ongoing equity stake in the company.

Filing Facts

CIK

882095

Ticker

GILD

Form

4

Source Type

sec

Accession

0001638643-26-000026

Alert Tier

8

ATTN Analysis